SIS
IOVA icon

Sound Income Strategies’s Iovance Biotherapeutics IOVA Stock Holding History

Sound Income Strategies’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-200
Closed -$1.48K – 1592
2024
Q4 		$1.48K Buy
+200
New +$1.85K ﹤0.01% 1222
2024
Q2 		– Sell
-50
Closed -$741 – 1435
2024
Q1 		$741 Buy
+50
New +$582 ﹤0.01% 1197

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Sound Income Strategies's IOVA Position: Q1 2025 in Review

Sound Income Strategies sold out of Iovance Biotherapeutics (IOVA) in Q1 2025, closing a stake of 200 shares — an estimated $1.48K sold.

Sound Income Strategies first reported a position in IOVA in Q1 2024 and held it in 2 quarters. The position peaked at $1.48K in Q4 2024. 301 funds tracked by Wall St. Rank hold IOVA as of Q1 2025.

  • Sound Income Strategies reported no remaining Iovance Biotherapeutics position as of Q1 2025 after selling out during the quarter.
  • Sound Income Strategies sold 200 Iovance Biotherapeutics shares in Q1 2025, an estimated $1.48K.
  • Sound Income Strategies first reported a position in Iovance Biotherapeutics in Q1 2024 and held it in 2 quarters.
  • Sound Income Strategies's Iovance Biotherapeutics position peaked at $1.48K in Q4 2024.
  • 301 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2025.

Based on Sound Income Strategies's 13F filing for Q1 2025, filed 17 Apr 2025.